Active Filter(s):
Details:
LucyTx-1209 and LucyTx-1212 are designed to target one of the functions of the protein complex F1F0-ATPase, which acts within the ETC. The Lucy Therapeutics compounds reduced levels of α-synuclein, which accumulate and are a pathological hallmark of PD.
Lead Product(s): LucyTx-1209
Therapeutic Area: Neurology Product Name: LucyTx-1209
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022